Researchers discover unexpected role of an immune system receptor; blocking it halts human cancer cell growth and improves survival in animal models
For some cancers, initial treatment with chemotherapy brings positive, but only temporary, results: tumors shrink, but then rebound as the cancer becomes drug-resistant. This pattern of remission-resistance-relapse is particularly true for pancreatic cancer, an aggressive disease in which early success is often countered by eventual disease progression.
To wit: The one-year relative survival rate for pancreatic cancer is 20 percent, according to the American Cancer Society. The five-year rate is just 7 percent.
The reason: Current multidrug chemotherapy regimens targeting pancreatic cancer typically do not fully eradicate all cancer cells, leaving behind drug-resistant cells that harbor aberrant stem cell properties and can drive tumor regrowth and metastasis.
In a new paper publishing in the April 4, 2019 online issue of Cell, an international team of scientists led by researchers at University of California San Diego School of Medicine employed an array of next-generation sequencing and gene-editing tools, such as CRISPR, to map the molecular dependencies —and thus vulnerabilities — of pancreatic cancer stem cells.
Most notably, they found that a key hormone receptor called retinoic acid receptor-related orphan receptor gamma or ROR?, previously studied in inflammation and T-cell differentiation, was especially active during pancreatic cancer progression, and that blocking it markedly slowed patient derived tumor growth and improved survival in animal models.
“These studies revealed an unexpected role for immuno-regulatory genes in the maintenance of the most aggressive, drug-resistant cells in pancreatic cancer,” said senior study author Tannishtha Reya, PhD, UC San Diego professor in the departments of Pharmacology and Medicine. In particular, ROR? emerged as a key regulator. ROR? rose with cancer progression and its inhibition through genetic and pharmacological approaches resulted in a striking defect in pancreatic cancer growth.
“Our work shows that immune system signals are hijacked by pancreatic cancer, and suggests that therapies currently being tested for autoimmune indications should be considered for testing in pancreatic cancer,” said Reya.
Using genome scale approaches to map stem cell dependencies in pancreatic cancer “will be invaluable for understanding the basis of therapy resistance and recurrence and for discovering new vulnerabilities in pancreatic cancer,” said Reya. “Beyond providing new scientific insight, this work can help identify pathways for which clinical grade inhibitors may already exist and can thus be rapidly tested in pancreatic cancer.”
In particular, she said the discovery of ROR?‘s role in promoting tumor growth provides a new avenue for research and potential therapies. “One exciting aspect is the possibility that nuclear hormone receptors could represent therapeutic targets for pancreatic cancer. In fact, drugs targeting ROR? have already been developed by several pharmaceutical companies, and are in trials for autoimmune diseases. Our findings suggest that these agents could also be a valuable therapeutic strategy for pancreatic cancer.”
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- Hopeful New Therapies For Pancreatic Cancer Expected to be a Big Boon for Biotechson January 22, 2020 at 4:50 am
PALM BEACH, Florida, Jan. 22, 2020 /PRNewswire/ -- Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is less than 10%. Treatment options for ...
- Naperville sixth-grader sells shoe, streetwear with designs he created to raise money for pancreatic cancer researchon January 22, 2020 at 4:49 am
When Wes Selby’s grandmother was diagnosed with stage 4 pancreatic cancer in 2019, the 12-year-old Naperville boy wanted to do something to bring her hope. Wes turned his passion for drawing into ...
- BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Canceron January 22, 2020 at 3:00 am
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today the completion ...
- Pancreatic Cancer Market Share Growing Rapidly with Recent Trends, Revenue and Forecast to 2025on January 21, 2020 at 7:29 am
New York, January 21, 2020: The Global Pancreatic Cancer Market is expected to exceed more than US$ 13 billion by 2024. Browse Full Report: ...
- Chi-Med stops pivotal pancreatic cancer trial upon early successon January 21, 2020 at 5:40 am
Hutchison China MediTech has stopped a phase 3 trial of surufatinib in pancreatic neuroendocrine tumors early for positive efficacy. An independent data monitoring committee found the trial had hit ...
- A link between metabolic energetics and pancreatic cancer mechanosensingon January 20, 2020 at 8:19 am
Extracellular-matrix remodelling contributes to tumour progression, results in intratumoural fibrosis and promotes metastatic behaviour. A new study by Papalazarou et al. now reveals that a pathway ...
- Health watch: Pancreatic cancer clinical trialson January 17, 2020 at 3:13 pm
SAN DIEGO — Did you know that January is National Pancreatic Cancer Clinical Trials Awareness Month? These clinical trials have been incredibly successful in recent years. Since 2011, the survival ...
- Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic canceron January 17, 2020 at 3:11 am
Here, we report the development of two novel mAbs against CFPAC-1 human pancreatic cancer cells. Using ELISA, flow cytometry, immunoprecipitation, mass spectrometry, Western blot and ...
- Portland ‘Jeopardy!’ Teen Tournament champ announces donations to OHSU pancreatic cancer researchon January 16, 2020 at 9:58 am
But Gupta didn’t just sit back and rest on his laurels. The Catlin Gabel graduate has donated $10,000 of his “Jeopardy!” winnings to the OHSU Knight Cancer Institute for pancreatic cancer research.
- Pulling the plug on calcium pumps -- potential new treatment strategy for pancreatic canceron January 16, 2020 at 7:32 am
UK scientists have identified a new way to kill pancreatic cancer cells by 'pulling the plug' on the energy generator that fuels calcium pumps on their cell surface. The study, published in the ...
via Bing News